undamentalytics Newsletter
Sign in

Immunome Inc. insider trading

Every open-market purchase and sale by Immunome Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $2.3M 9 trades by 3 insiders 3 months later: median +1.8% (−2.2% vs S&P 500) Insider sales, 5 years $27.5M 21 trades by 7 insiders 3 months later: median −6.0% (−10.1% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Immunome Inc.’s insiders pay?

From May 26, 2021 to June 9, 2026, 12 insiders reported 29 open-market purchases and 4 sales not made under a pre-set plan in Immunome Inc. Twelve months after each purchase was reported, the shares were +14.4% against the S&P 500 on average (median +30.2%), over 21 purchases with a full year of prices; 52% beat the index. After sales, the shares moved −46.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 27, 2021 into $6,053 by November 2, 2026, −8.9% a year. It held shares 81% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,416 (+11.9% a year), and held throughout $19,415 (+13.0%).

$0$10.0k$20.0k 202120222023202420252026 $19.4k$18.4k$6.1k
Copying Immunome Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Immunome Inc.'s insiders from May 27, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 81% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Bienaime Jean Jacques Director 8 +59.0% (5) 60% 1 — June 9, 2026
Siegall Clay B President and CEO 9 +55.2% (5) 80% 0 — March 31, 2026
Rapp Michael Director 3 −72.0% (3) 0% 0 — September 14, 2021
Tsai Philip Chief Technical Officer 3 +104.0% (2) 100% 0 — December 22, 2025
Wagenheim Philip Director 1 −83.9% (1) 0% 1 — March 23, 2026
Higgins Jack Chief Scientific Officer 0 — — 1 −49.2% (1) August 19, 2024
Lamattina John L Director 1 −83.9% (1) 0% 0 — May 26, 2021
Lechleider Robert Chief Medical Officer 1 +44.3% (1) 100% 0 — November 25, 2024
Lefenfeld Michael Director 1 −83.9% (1) 0% 0 — May 26, 2021
Rosett Max Chief Financial Officer 0 — — 1 −44.4% (1) September 20, 2024
Sarma Purnanand D President and CEO 1 −83.9% (1) 0% 0 — May 26, 2021
Turner Bruce Chief Strategy Officer 1 +30.2% (1) 100% 0 — October 4, 2023

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Immunome Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Immunome Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 7 buying crowds with six months of prices, it averaged −1.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
April 30, 20262 buying−5.0%−27.9%not yet
December 31, 20252 buying+5.2%+0.5%not yet
March 31, 20253 buying+15.0%+54.2%+215.1%
November 29, 20243 buying−28.4%−33.0%+28.1%
May 31, 20242 buying−5.6%−24.3%−54.1%
October 31, 20232 buying+69.5%+48.5%−7.5%
May 28, 20215 buying−38.9%−28.9%−83.8%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Immunome Inc. · Funds · Politicians